Commentary on ‘Iliac Conduits for Endovascular Repair of Aortic Pathologies’  by Milner, R.
INVITED COMMENTARYCommentary on ‘Iliac Conduits for Endovascular Repair of Aortic
Pathologies’
R. Milner *
University of Chicago Medical Center, Vascular Surgery, 5841 South Maryland Avenue, MC5028, Chicago, IL 60637, USAImprovements in endograft design and their delivery
systems have decreased the overall risks associated with
thoracic endovascular repair (TEVAR). But, the procedure is
still complicated by the morbidity and mortality associated
with peri-operative neurologic events and life-threatening
arterial injuries that occur due to large proﬁle delivery
systems for the larger diameter TEVAR devices. Surgeons
have become very comfortable with placing an iliac artery
conduit as a means to insert large proﬁle devices with an
assumed reduction in the morbidity and mortality of TEVAR
as compared to open repair or complications from an iliac
artery injury. These surgical skills have now been widely
applied for TAVR use in the United States since approval of
the ﬁrst percutaneous valve technology here.
Ricotta et al. have now provided data that is contrary to
the above opinion concerning the implied safety for
patients in placing an iliac conduit. The authors used the
American College of Surgeons Surgical Quality Improve-
ment Program database to evaluate iliac conduit use
during TEVAR and then evaluate patient outcomes. The
study reviewed data from patients during the years of
2005e2010 and included two groups comparing conduit
use and femoral access. 117 patients (10% of the total
population) had an iliac artery conduit placed in order to
deliver the device. It was more common for women to
receive a conduit as compared to men. And, the surgical
complications and mortality were signiﬁcantly higher in the
conduit group. Speciﬁcally, the use of a conduit carried
a 3.8 times higher risk of death as compared to not using
a conduit.
I believe that this manuscript highlights some important
data regarding the risks of iliac artery conduits. It is inter-
esting that the overall use of conduits decreased during thisDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2013.01.037
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http://dx.doi.org/10.1016/j.ejvs.2012.12.016study period. The decrease is certainly due to familiarity
with TEVAR techniques and improvements in endograft
delivery systems. But, I am reluctant to abandon conduit
use based on this data alone.
The registry nature of the ACS SQIP allows for a large
number of patients to be compared and is clearly one of
the strengths of this research technique. But, the downside of
the data is that we do not understand any of the important
factors that determined the need for the placement of a
conduit for theseprocedures.Thedatabase does not havedata
entry ﬁelds for iliac artery diameter, calciﬁcation or tortuosity.
The database does not have a ﬁeld that requires a surgeon to
enter data on why a conduit was selected. The database does
not allow a comparison of the TEVAR technology utilized. And,
ﬁnally, we have no idea if any of the conduit patients were
candidates for the alternative of open thoracic aortic surgery.
In light of these concerns with the database utilized, it
has raised some skepticism for me as to why the increased
morbidity and mortality is seen with conduit use in these
patients. But, either way, the data demonstrates the
increased risk to be the case. The limitations of the ACS
SQIP do not allow further risk stratiﬁcation so that we can
recommend not treating patients that are clearly too high
risk, even for a TEVAR via an iliac conduit approach. But, it
seems that women are at higher risk as is any conduit
patient. The data from this manuscript will assist me in
carefully assessing my patients for their overall risk before
just assuming a conduit is a safe approach for a patient.
The authors state this point perfectly from my perspec-
tive. “Safer access for TEVAR by use of a conduit should not
be abandoned based on these results, but there should be
a heightened awareness for the higher rate of mortality in
these patients.”
